Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II active comparator study with injectable RT 002 [botulinum toxin A] for the treatment of glabellar lines

Next Previous
Trial Profile

Phase II active comparator study with injectable RT 002 [botulinum toxin A] for the treatment of glabellar lines

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daxibotulinumtoxin A (Primary)
  • Indications Glabellar lines
  • Focus Therapeutic Use
  • Acronyms BELMONT
  • Sponsors Revance Therapeutics

Most Recent Events

  • 01 Nov 2017 Results published in the Dermatologic Surgery
  • 15 Jun 2017 According to a Revance Therapeutics media release, results from this trial published in the Dermatologic Surgery journal.
  • 03 Mar 2017 According to a Revance Therapeutics media release, data will be presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top